## Quantitative Susceptibility Mapping (QSM) in Wilson's Disease

Andreas Schäfer<sup>1</sup>, Dominik Fritzsch<sup>2</sup>, Peter Günther<sup>3</sup>, Robert Trampel<sup>1</sup>, Robert Turner<sup>1</sup>, and Karl-Titus Hoffmann<sup>2</sup>

<sup>1</sup>Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany, <sup>2</sup>Department of Neuroradiology, University of Leipzig, Leipzig, Germany, <sup>3</sup>Department of Neurology, University of Leipzig, Leipzig, Germany

**PURPOSE:** Accumulation of metallic compounds in the human brain has been shown in some neurodegenerative diseases. In Parkinson's disease iron content seems to be increased in the basal ganglia [1], whereas in Alzheimer's disease zinc and iron are increased [2]. Recently it was shown that quantitative susceptibility mapping (QSM) is very sensitive to paramagnetic effects of iron [3], supporting the differentiation of Parkinson patients from healthy controls using MRI and QSM [4]. Wilson's disease is a neurodegenerative disease with symptoms rather similar to Parkinson's disease and other movement disorders, but in Wilson's disease the copper content is increased [5]. The aim of this study is to investigate whether copper accumulation in the brain of Wilson's patients can be detected using QSM, by comparison with healthy controls.

**METHODS:** 8 patients with Wilson's disease (23-64 years, mean 44 years, 4 female) and 10 age-matched healthy controls (27-61 years, mean 45 years, 5 female), who gave informed consent, were examined on a whole body 7T scanner using a 24 channel phased array coil. The study was approved by the local ethics committee. For imaging a 3D spoiled gradient multi-echo sequence (TR=40 ms; TE=9.76/19.19/28.62 ms; bw=150 Hz/pixel; voxel=0.6x0.6x0.8mm<sup>3</sup>) was used.

The phase data, which show the effects of a field perturbation  $B_{dz}(\mathbf{r})$ , were unwrapped using a 3D best-path phase unwrapping algorithm [6]. The SHARP algorithm was used to remove any  $B_0$  inhomogeneities and thus obtain high-pass filtered phase data [7]. The filtered phase data were divided by  $\gamma B_0 \text{TE}$  to convert the field-shift to units of ppm. The data were re-sampled to 0.6 mm isotropic resolution. The susceptibility was then calculated by  $\chi(\mathbf{r})=\text{FT}^{-1}(-3 \cdot B_{dz}(\mathbf{k})/B_0 \cdot \text{C}^{-1}(\mathbf{k}))$ , where  $B_{dz}(\mathbf{k})$  is the field perturbation in *k*-space,  $B_0$  the main magnetic field and  $C(\mathbf{k})=3k_z^2/|\mathbf{k}|^2-1$  the convolution kernel. Before inverse Fourier transform values of the convolution kernel smaller than 1.3 were set to signum( $C(\mathbf{k})$ )·1.3 to reduce noise amplification and minimise streaking artefacts [8]. So far we only analysed the Substantia Nigra (SN).

**RESULTS:** Figure 1 shows an example of the gradient echo magnitude image, phase image and the calculated QSM for one patient. The average value of the susceptibility of the SN is  $0.23\pm0.08$  ppm and  $0.13\pm0.03$  ppm for patients and healthy controls, respectively. Figure 2 shows the susceptibility of the SN of the Wilson's patients (red) and healthy controls (green). 6 out of 8 patients show an increased susceptibility within the SN compared to healthy controls.



**DISCUSSION:** Our data clearly show that the SN is more paramagnetic in Wilson's disease patients compared to healthy controls. The remaining question is: What induces the change in magnetic behavior? The element copper is only slightly more paramagnetic than water, and copper(I)-compounds are even more diamagnetic than water [9]. One possible explanation is that copper(II)-compounds, which mostly have strong paramagnetic behavior, yield the increased paramagnetic behavior of Wilson's patients.

**CONCLUSION:** We have successfully applied QSM to Wilson's disease patients. There is a trend that paramagnetic copper(II) induces the magnetic susceptibility changes in patients as compared to controls. Further investigations will include quantitative T1 mapping, since copper(II) also enhances the longitudinal relaxation rate [10].

## **REFERENCES:**

[1] Gorell et al., Neurology 45:1138-1143 (1995); [2] Duce et al., Cell 142:857–867 (2010); [3] Langkammer et al., NeuroImage 62:1593-1599 (2012); [4] Lotfipour et al., Journal of Magnetic Resonance Imaging, 35:48-55 (2012); [5] Lorincz et al., Ann N Y Acad Sci. Jan;1184:173-87(2010); [6] Abdul-Rahman et al., Appl. Opt. 46:6623–6635 (2007); [7] Schweser et al., NeuroImage 54:2789-2807 (2011); [8] Schweser et al., MRM (in press, DOI: 10.1002/mrm.24405); [9] Lide "CRC Handbook of Chemistry and Physics, CRC Press (2009); [10] Owens et al., J. Am. Chem. Soc. 108:3298-3303 (1986)